A case of 5-FU-related severe toxicity associated with the p.Y186C DPYD variant

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 2, 2014, Pages 136-

  Zaanan, A ^a,b   Dumont, L M ^a   Loriot, M A ^a,b   Taieb, J ^a,c   Narjoz, C ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICANS; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; MALE; NEOPLASMS;

EID: 84893797165     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.183     Document Type: Letter

References (5)

1. Offer, S.M., Lee, A.M., Mattison, L.K., Fossum, C., Wegner, N.J. & Diasio, R.B. A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity. Clin. Pharmacol. Ther. 94, 158-166 (2013).
2. Capitain, O., Asevoaia, A., Boisdron-Celle, M., Poirier, A.L., Morel, A. & Gamelin, E. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: A phase II, proof-of-concept study. Clin. Colorectal Cancer 11, 263-267 (2012).
3. Coudoré, F. et al. Validation of an ultrahigh performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma. J. Chromatogr. Sci. 50, 877-884 (2012).
4. Boisdron-Celle, M. et al. 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 249, 271-282 (2007).
5. Caudle, K.E. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. (2013); e-pub ahead of print 29 August 2013.